Extraordinary. And not in a good way

Very proud and excited about this paper - we present results of the first #genesilencing treatment in #alzheimers disease and show robust dose & time related reduction in tau levels. Phase 2 ongoing! ⁦DRC@UCL⁩ ⁦NIHR UCLH Biomedical Research Centre⁩ #curedementia nature.com/articles/s4159…

Very exciting times!

Congrats Tom Veale! Very well deserved.

Excellent presentation by Dave Cash showing amyloid and tau PET data from our LHA @ UCL Insight 46 data led by Will Coath and funded by Marc Zacher Alzheimer's Association Research at ARUK

The Consultants of Dorset hospital have written a letter to Steve Barclay They strike tomorrow This letter is incredible I challenge anyone to refute a single point in it Worth a read for you too Wes Streeting

I’m very happy and honoured to be named as a UKDRI Emerging Leader. Excited about the great opportunities to collaborate closely with amazing colleagues from across the DRI over the coming years.

Pleased to share this update by Dr Anna Volkmer, Charles Marshall and friends, identifying six of many vexing issues surrounding primary progressive aphasia link.springer.com/article/10.100…

Immunotherapies for Alzheimer’s disease, well written review hard to grumble with any of these thoughts and predictions science.org/doi/10.1126/sc…

Best way to start the new year: our paper on the role of CSF GAP-43 in amyloid-associated tau spread is out in Nature Communications. Great work led by Nico Franzmeier!

Cortical thinning in regions typically associated with Alzheimer’s may relate to vascular disease! Our latest from LHA @ UCL Insight 46 study *open access* in Journal of Neurology, Neurosurgery and Psychiatry jnnp.bmj.com/lookup/content…

The era of commercial #blood tests for #Alzheimer disease is near. We evaluate the ALZpath #pTau217 blood test in 3 independent cohorts🇺🇸🇨🇦🇪🇸 ➡️ Consistent high acc. for amyloid & tau (>0.95) ➡️ Reproducible cut-offs ➡️ ~80% reduction in adv. testing jamanetwork.com/journals/jaman…

NHS England » Dementia programme and preparation for new Alzheimer’s disease modifying treatments - good to see strategy outlined. Critical that clinicians and triallists are involved in discussions on roll out as they have direct experience of use england.nhs.uk/long-read/deme…

Great opportunity to join us as a clinical research fellow on the familial #Alzheimer disease team DRC@UCL ucl.ac.uk/work-at-ucl/se…

Great to see coverage on BBC news re treatment for Everyday Health. Watch BBC Panorama for the full story where I speak w/Fergus Walsh on new Alzheimer's meds. Benefits are modest but show potential for a new generation of effective therapies. 1/2 bbc.co.uk/programmes/m00…

Helen Rice RareDementiaSupport Such an incredible and inspirational group of people. It was great to get to know them a bit better in the pub afterwards!

Out today in The Lancet Neurology — we review excess brain volume loss following amyloid immunotherapy and conclude that it is *not* related to neuronal loss. Download here: authors.elsevier.com/c/1jnzE5FFzL0E… #ARPA Chris Belder The Lancet Neurology

I’ll be running the London Marathon in three weeks time 😬 to raise money for the National Brain Appeal, a fantastic charity that works to advance treatment and support for those with neurological disease. Any donations are very much appreciated. 😃🙏 justgiving.com/page/phil-west…